COVID-19 Vaccination in Pregnancy (2021)

Key points

• The Joint Committee on Vaccination and Immunisation (JCVI) now advises that if a pregnant woman meets the definition of being clinically extremely vulnerable, or is a frontline health or social care worker, then she is eligible to receive a COVID-19 vaccine..
• There is currently a lack of efficacy and safety data for COVID-19 vaccines for pregnant women, and an urgent need to provide information to inform women's choice.

Surveillance period

1^st February 2021 – 31^st March 2021

Background

The Joint Committee on Vaccination and Immunisation (JCVI) now advises that if a pregnant woman meets the definition of being clinically extremely vulnerable, or is a frontline health or social care worker, then she is eligible to receive a COVID-19 vaccine. Further information, including a decision aid to support pregnant women offered COVID-19 vaccination make a personal informed choice is available on the dedicated RCOG COVID-19 vaccination hub

Although there is no known risk associated with giving other non-live vaccines to pregnant women, there is currently a lack of efficacy and safety data for COVID-19 vaccines for pregnant women, and an urgent need to provide information to inform women's choice.

Objective

To use the UK Obstetric Surveillance System (UKOSS) and UK Teratology Information Service (UKTIS) to describe the current population of women receiving Covid-19 vaccination in pregnancy and assess the outcomes of pregnancy for mother and infant.

Research questions

• What are the characteristics of women receiving Covid-19 vaccination in pregnancy?
• What are the outcomes of pregnancy for mother and infant and how do these compare to a historical comparison group of women with comparable health conditions?

Case definition

Any pregnant woman who has received the Covid-19 vaccination at any stage during her pregnancy.

Methods

Case notification will be undertaken through UKOSS, with data collection forms returned to

UKTIS (nuth.contactUKTIS@nhs.net).

Ethics committee approval

This study has been approved by the North London REC1 (Ref. Number: 10/H0717/20).

Lead investigators

Professor Marian Knight, National Perinatal Epidemiology Unit, University of Oxford

Dr Ken Hodson, Head of UK Teratology Information Service, University of Newcastle

Professor Lucy Chappell, Vaccine cell lead, Royal College of Obstetricians and Gynaecologists

Download the Data Collection Form (DCF)

UKOSS COVID19 Vaccine Baseline Data Form